Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil

Next Previous
X
Search
Trial Profile

Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idalopirdine (Primary) ; Donepezil
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms STARSHINE
  • Sponsors Lundbeck A/S

    • Most Recent Events

    • 09 Jan 2018 Results of pooled data from three trial (NCT01955161, NCT02006641 and NCT02006654) assessing whether idalopirdine is effective for symptomatic treatment of mild to moderate AD, were published in the JAMA: the Journal of the American Medical Association.
    • 20 Jul 2017 Results (n=2525) from STAR Phase III Program (NCT01955161, NCT02006641, NCT02006654), presented at the Alzheimer's Association International Conference 2017.
    • 23 Sep 2016 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top